Envestnet Asset Management
AUTL

Envestnet Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Envestnet Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-41,812
Closed -$267K – 4173
2024
Q1 		$267K Buy
41,812
+20,641
+97% +$129K ﹤0.01% 3784
2023
Q4 		$136K Buy
+21,171
New +$80.7K ﹤0.01% 3906

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Envestnet Asset Management's AUTL Position: Q2 2024 in Review

Envestnet Asset Management sold out of Autolus Therapeutics (AUTL) in Q2 2024, closing a stake of 41,812 shares — an estimated $267K sold.

Envestnet Asset Management first reported a position in AUTL in Q4 2023 and held it in 2 quarters. The position peaked at $267K in Q1 2024. 111 funds tracked by Wall St. Rank hold AUTL as of Q2 2024.

  • Envestnet Asset Management reported no remaining Autolus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Envestnet Asset Management sold 41,812 Autolus Therapeutics shares in Q2 2024, an estimated $267K.
  • Envestnet Asset Management first reported a position in Autolus Therapeutics in Q4 2023 and held it in 2 quarters.
  • Envestnet Asset Management's Autolus Therapeutics position peaked at $267K in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2024.

Based on Envestnet Asset Management's 13F filing for Q2 2024, filed 8 Aug 2024.